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Mutations in PNPLA6 are linked to photoreceptor
degeneration and various forms of childhood
blindness
S. Kmoch1,*, J. Majewski2,*, V. Ramamurthy3,*, S. Cao4,5, S. Fahiminiya2, H. Ren4,5, I.M. MacDonald6, I. Lopez4,5,
V. Sun4,5, V. Keser4,5, A. Khan4,5, V. Stra´necky´1, H. Hartmannova´1, A. Prˇistoupilova´1, K. Hodanˇova´1,
L. Piherova´1, L. Kucharˇ1, A. Baxova´7, R. Chen8, O.G.P. Barsottini9, A. Pyle10, H. Grifﬁn10, M. Splitt10, J. Sallum11,
J.L. Tolmie12, J.R. Sampson13, P. Chinnery10, Care4Rare Canadaz, E. Banin14, D. Sharon14, S. Dutta15, R. Grebler16,
C. Helfrich-Foerster16, J.L. Pedroso9, D. Kretzschmar15, M. Cayouette3,17,18 & R.K. Koenekoop4,5
Blindness due to retinal degeneration affects millions of people worldwide, but many disease-
causing mutations remain unknown. PNPLA6 encodes the patatin-like phospholipase domain
containing protein 6, also known as neuropathy target esterase (NTE), which is the target of
toxic organophosphates that induce human paralysis due to severe axonopathy of large
neurons. Mutations in PNPLA6 also cause human spastic paraplegia characterized by motor
neuron degeneration. Here we identify PNPLA6 mutations in childhood blindness in seven
families with retinal degeneration, including Leber congenital amaurosis and Oliver McFarlane
syndrome. PNPLA6 localizes mostly at the inner segment plasma membrane in photo-
receptors and mutations in Drosophila PNPLA6 lead to photoreceptor cell death. We also
report that lysophosphatidylcholine and lysophosphatidic acid levels are elevated in mutant
Drosophila. These ﬁndings show a role for PNPLA6 in photoreceptor survival and identify
phospholipid metabolism as a potential therapeutic target for some forms of blindness.
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P
NPLA6 (also previously referred to as neuropathy target
esterase (NTE)) is a highly conserved lysophospholipase
anchored to the cytoplasmic face of the endoplasmic
reticulum (ER)1–3. It is the primary target of toxic organo-
phosphorous compounds (found in agricultural pesticides and
agents of chemical warfare) that cause axonal degeneration in
large neurons. Human organophosphorous-induced delayed
neuropathy (OPIDN) occurs when PNPLA6 becomes phos-
phorylated by these organophosphates, followed by dealkylation
of the phosphoryl enzyme, inhibiting the catalytic domain4,5.
Patients with mutations in the catalytic domain of PNPLA6
develop a Mendelian motor neuron disease called spastic
paraplegia (SPG39), which is characterized by distal
degeneration of motor axons surprisingly similar to OPIDN6,7.
The exact mechanism of PNPLA6 function in both OPIDN and
SPG39 remains unknown8.
PNPLA6 is expressed in the brain, where it deacetylates
phosphatidylcholine (PC) to lysophosphatidylcholine (LPC) and
LPC to glycerophosphocholine1,9. In Drosophila, the Swiss cheese
protein (sws; the orthologue of vertebrate PNPLA6) is involved in
the regulation of membrane lipid homeostasis and in the survival
of both neurons and glia as well10. In mice, Pnpla6-deﬁcient
animals are embryonic lethal11 but brain-speciﬁc mutants show
neurodegeneration12, and there is much evidence that PNPLA6 is
involved in maintaining nervous system integrity13,14.
Interestingly, mice expressing a single copy of Pnpla6 are viable
but show increased sensitivity to organophosphorous toxins11.
In this work, we identiﬁed biallelic PNLPA6 mutations in
patients with childhood blindness due to severe photoreceptor
death and clinical features of Leber congenital amaurosis (LCA)
and, interestingly, also of the rare Oliver McFarlane syndrome
(OMS; OMIM 275400). OMS patients have a complex phenotype
characterized by blindness due to severe photoreceptor degenera-
tion, dwarﬁsm due to pituitary growth hormone deﬁciency,
trichomegaly and progressive alopecia. Occasionally, OMS is
associated with mental retardation, distal muscle weakness/
wasting and ataxia, due to axonal peripheral neuropathy. We
document PNPLA6 expression in mouse and Drosophila retina,
and test phenotypic and metabolic consequences (phospholipids)
of PNLPA6 and SWS mutations in humans and Drosophila,
respectively. We show that PNPLA6 has a role in photoreceptor
survival and identify phospholipid metabolism as a potential
therapeutic target for some forms of blindness.
Results
Identiﬁcation of PNPLA6 mutations in OMS. Our initial goal
was to discover the causal genetic mutations for two sporadic cases
(5,267 and 5,273) in two Canadian families and three affected
siblings (166, 167 and 169), in a third OMS family from the Czech
Republic (Fig. 1). Although most OMS cases seem to be sporadic,
segregation patterns of the phenotype support the recessive mode
of inheritance. We therefore hypothesized that we could identify
the unknown causal gene by excluding all genomic variants, except
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Figure 1 | PNPLA6 mutations in individuals from seven families with childhood blindness. Sequencing reads are aligned against positive strand of
hg19. Vertical arrows represent the 100 paired-end reads in 5,267 and 5,273 patients, respectively. Both patients carry heterozygous mutations in
PNPLA6: 5,267 has 2 missense mutations c.1571T4C (leucine to proline substitution at codon 524) and c.3373G4A (aspartic acid to asparagine at
codon 1125). Patient 5,273 has a nonsense mutation c.2116C4T, which result in a glutamine to stop codon at codon 706, leading to loss of the last
669 amino acids of the protein and a missense mutation c.3385G4C glycine to arginine at codon 1129. All of the complementary DNA positions are
based on PNPLA6 NM_001166111.1. Moreover, shown are seven families/pedigrees with various forms of childhood blindness due to photoreceptor
degeneration in OMS and LCA. Chromatograms of the PNPLA6 mutations, pedigrees and co-segregation of the mutations are shown for each family
(Supplementary Fig. 1).
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms6614
2 NATURE COMMUNICATIONS | 6:5614 | DOI: 10.1038/ncomms6614 | www.nature.com/naturecommunications
& 2015 Macmillan Publishers Limited. All rights reserved.
those biallelic variants that we would ﬁnd in the same gene in the
ﬁve affected OMS patients (assuming one gene for OMS). Whole
exome sequencing (WES) ﬁrst excluded such mutations in the
currently known 210 retinal disease genes. We then sifted through
thousands of variants and identiﬁed that all ﬁve patients harboured
and shared biallelic variants in PNPLA6 and not in any other gene
(Fig. 1). We identiﬁed six missense mutations in these three OMS
families in PNPLA6 (NM 001166111.1). With Sanger sequencing,
we conﬁrmed co-segregation in two out of the three families (one
family was deceased) and excluded the variants from 100 normal
controls. We then recruited ﬁve more OMS families from around
the world (Fig. 1), and overall we identiﬁed ten novel PNPLA6
mutations (Fig. 2b and Supplementary Fig. 1) in a total of seven
families. Only one OMS family did not harbour PNPLA6 muta-
tions, suggesting allelic heterogeneity and thus a second OMS-
causing gene. We then searched for PNPLA6 mutations in 200
cases with LCA that had undergone WES and found one patient
with signiﬁcant autism and two PNPLA6mutations. We discovered
a total of ﬁve missense, two nonsense, two frameshift and one splice
site mutation(s) in PNPLA6 (Figs 1 and 2). One of the mutations,
that is, p. Gly1129Arg was found three times, while another
mutation, that is, p. Asp1125Asn was identiﬁed twice, affecting
residues in the evolutionarily highly conserved patatin domain
(down to Escherichia coli; Fig. 2c). In ﬁve out of seven patients, we
found compound heterozygous missense mutations in both the
regulatory (amino-terminal) and in the catalytic domain (carboxy-
terminal). The missense mutations are all in residues that are very
well conserved (Fig. 2c). Targeted DNA screening revealed that the
mutations found in the affected individuals are rare, as they were
absent from 41,000 WES samples in our in-house databases of
which at least 200 patients were genetically unsettled LCA.
Genotype/phenotype correlations in the cohort. All except one
patient had OMS, as per standard clinical diagnostic criteria, with
some patients exhibiting ataxia, mental retardation, or peripheral
neuropathy. Detailed phenotypes are described in Table 1. All our
OMS patients had signiﬁcant retinal degeneration with photo-
receptor death and blindness, long lashes and dwarﬁsm. The
retinal degeneration is severe and early onset, with photoreceptor
death, but also with inner retinal changes and retinal thinning
accompanied by lipofuscin metabolism abnormalities (Fig. 3).
In proband 5,267 from family 1, we found two missense
mutations (Figs 1 and 2b and Supplementary Fig. 1) One of the
missense mutations resides in a residue in the regulatory region and
the second in the catalytic region (patatin domain) (Fig. 2). Brieﬂy,
this affected French–Canadian child with OMS developed nycta-
lopia (signiﬁcant nightblindness) at the age of 2 years. At age 9
years, she had 20/1,200 visual acuities from severe retinal and
choroidal degeneration (Fig. 3a), with diffuse photoreceptor loss
(Fig. 3b), growth retardation and long lashes, but high intelligence.
In proband 5,273 from family 2 with OMS, we found a nonsense
mutation in the regulatory region and a missense mutation in the
patatin domain of PNPLA6 (Figs 1, 2b and Supplementary Fig. 1).
This 30-year-old Scottish male had light perception vision
photoreceptor loss, dwarﬁsm, peripheral neuropathy and ataxia.
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Figure 2 | Mutations identiﬁed in PNPLA6 patients. Shown here is the genetic structure (a) and the protein structure (b) with all the mutations (ten)
identiﬁed in the current study indicated above the PNPLA6 protein. Previously reported mutations causing the paraplegia syndrome (SPG39) are
shown below the protein. A line-up of the affected protein regions from various species (from E. coli to man) is shown in c, showing the marked and
signiﬁcant evolutionary conservation of the residues, some down to E. coli.
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In cases 166, 167 and 169 from the Czech OMS family 3 we found a
splice site mutation in the regulatory region and a missense
mutation in the patatin domain (Fig. 2b and Supplementary Fig. 1).
The three affected members had severe photoreceptor degeneration,
dwarﬁsm, long lashes, normal intelligence, ataxia and peripheral
neuropathy. Proband 3,649 from family 4 with LCA was found to
have a frameshift in the catalytic region and a missense mutation in
the regulatory region of PNPLA6 (Fig. 2b and Supplementary
Fig. 1). This Caucasian child had congenital visual loss and
signiﬁcant autism but no other systemic disease. Proband 5,477
from family 5 with OMS was found to have two missense
mutations, both in the catalytic region, which co-segregate through
this Brazilian family (Fig. 2b and Supplementary Fig. 1). The
affected child has severe visual loss (counting ﬁngers vision) from
photoreceptor degeneration, long lashes, short stature, mild mental
handicap and neuropathy with ataxia. Proband 5,440 from family 6
with OMS from Scotland carried a frameshift mutation in the
regulatory region and a missense mutation in the catalytic region of
PNPLA6, which co-segregated in the family (Fig. 2b and
Supplementary Fig. 1). The affected child was noted to have
congenital nystagmus from photoreceptor degeneration, normal
mentation and lashes, but short stature and a motor neuropathy.
Proband 5,748 from family 7 with OMS from Great Britain was
found to harbour a nonsense mutation in the regulatory region of
PNPLA6, shared by the father of the affected child, but we could not
identify the maternal mutation (Fig. 2b and Supplementary Fig. 1).
PNPLA6 is expressed in mouse and ﬂy photoreceptors. All our
subjects with PNPLA6 mutations have photoreceptor degenera-
tion resulting in blindness. However, PNPLA6 mutations asso-
ciated with SPG39 and OPIDN diseases are not known to cause
retinal degeneration or blindness. As it was previously not known
whether PNPLA6 is expressed in retinal tissue, we investigated the
spatiotemporal retinal expression pattern of the PNPLA6 ortho-
logues in Drosophila (SWS) and in mouse retina (Fig. 4a,b). Using
an anti-serum against ﬂy SWS, we found expression around
photoreceptor nuclei and along the entire photoreceptor (Fig. 4c).
Performing co-stainings with the plasma membrane marker anti-
horseradish peroxidase, we found that some of the SWS is asso-
ciated with the plasma membrane, but that it can also be found in
the cytoplasm (Supplementary Fig. 2). This is in agreement with
our previous results in central nervous system neurons, which
showed that SWS can be detected in the ER10. In the mouse, we
found PNPLA6-expressing cells in both developing and adult
retinas (Fig. 4d–f). Co-staining of PNPLA6 with cell-type-speciﬁc
Table 1 | Complex phenotypes associated with PNPLA6 mutations.
Patient MOGL
study
5,267 5,273 166 167 169 3,649 5,477 5,440 5,748
Gender F M F F M M F F M
Age at ﬁrst
exam (years)
9 29 3 3 16 0 2 2 0
Birth weight
(kg)
2 kg NA 3 kg 3.3 kg 1.9 kg NA 2.5 kg 2.5 kg 2.4 kg
Height Short Short Short Short Short Normal Short/
Dwarﬁsm
Short Short
Bone age Delayed NA NA NA Normal None Delayed Delayed Delayed
Trichomegaly Yes Yes Yes Yes Yes No NA Normal NA
Hair Normal Sparse Alopecia Normal Alopecia Normal Alopecia Alopecia NA
Retinal
degeneration
Yes Yes Yes Yes Yes Yes Yes Yes Yes
GH deﬁciency Yes Yes Yes Yes Yes None Yes Yes Yes
Hypothyroidism Yes Yes None None None None Yes Yes Yes
Hypogonadism None None Yes Yes Yes None Yes Yes Yes
Mental
retardation
None None None None None Autism Mild None Yes
Peripheral
neuropathy
and/or ataxia
None Yes Yes Yes Yes None Yes Motor
neuropathy
Yes
Inheritance Sporadic Sporadic AR AR AR Sporadic NA Sporadic Sporadic
Chromosome NA 46 XY 46 XX 46 XX 46 XY NA NA 46 XY NA
Age when last
seen (years)
9 30 22 22 31 20 23 54 20
VA 20/400 OD
20/400 OS
Light
perception
with
projection in
both eyes
NA NA NA Counting
ﬁngers
Lower than
20/400
Light
perception
only
20/200 OD
20/80 OS
GVF No
measurable
ﬁeld
No
measurable
visual ﬁeld
NA NA NA No
measurable
ﬁeld
No
measurable
ﬁeld
No
measurable
ﬁeld
Peripheral
constriction
ERG No
recordable
responses
No
recordable
responses
NA NA NA NA NA No
recordable
responses
NA
Retinal
appearance
Severe
degeneration
Severe
degeneration
Severe
degeneration
Severe
degeneration
Severe
degeneration
Severe
degeneration
Severe
degeneration
Severe
degeneration
Severe
degeneration
Cancer None None None None None None None None None
Dental history None Chalky white
teeth,
numerous
cavities
tooth
development
abnormalities
tooth
development
abnormalities
tooth
development
abnormalities
None None Delay in
dentition
None
Comments None None Severe neonatal
hyperbilirubinemia
Severe neonatal
hyperbilirubinemia
Severe neonatal
hyperbilirubinemia
Nystagmus Retinal
sparing
around the
optic disc.
Optic disc
normal
appearance
Mild
elevation of
LFTs
Thoracic
lumbar
scoliosis
ERG, electroretinograms; F, female; GH, growth hormone; GVF, Goldmann visual ﬁeld; LFT, liver function tests; M, male; NA, not available; OD, oculus dexter; OS, oculus sinister; VA, Snellen visual acuity.
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markers showed restricted expression in horizontal, amacrine and
photoreceptor cells (Fig. 4g–o), but not in ganglion cells (not
shown). To determine the subcellular localization of PNPLA6 in
photoreceptors, we co-stained adult mouse retinal sections with
PNPLA6 and the inner segment (IS) plasma membrane marker
Naþ /KþATPase. Three-dimensional confocal imaging revealed
clear co-labelling (Fig. 4p–r), indicating primarily IS plasma
membrane localization in adult photoreceptors, although some
intracellular staining was also observed (Fig. 4q). Interestingly,
PNPLA6 was not found in the outer segments (OS). Peanut
agglutinin co-staining in adult mice showed that PNPLA6 is also
expressed in cones (Fig. 4s–u).
PNPLA6 is required for photoreceptor survival in Drosophila.
To study the consequences of PNPLA6 loss, we analysed the
recessive sws1-null mutant in Drosophila, which shows severe age-
dependent neurodegeneration15 starting around day ﬁve of
adulthood, but no overt eye phenotype. Electron microscopic
studies from sws1 ﬂies shortly before eclosion revealed that the
eye developed normally with all photoreceptors present (Fig. 5b).
Whereas 14-day-old ﬂies still had mostly intact ommatidia
(occasionally one photoreceptor was lost, arrow, Fig. 5c), at 23
days the photoreceptors were either lost (arrows, Fig. 5d) or
showed degenerative signs such as condensed cell bodies
(arrowheads, Fig. 5d,f), intracellular membranous bodies
(arrow, Fig. 5g), or vacuoles (arrowhead, Fig. 5h). Thirty-day-
old wild-type ﬂies did not reveal any of these phenotypes
(Fig. 5a,e). To exclude that the photoreceptor degeneration is a
secondary effect of the brain degeneration in sws1, we also
analysed an eye-speciﬁc knockdown of SWS using GMR-GAL4.
Again, the photoreceptors developed normally (Fig. 5i,m) and still
appeared unaffected in 7-day-old ﬂies (Fig. 5j,n), but when 30
days old ﬂies showed obvious signs of degeneration (Fig. 5k,o,
arrows) and some photoreceptors were lost (Fig. 5k, arrowhead).
To determine whether the degeneration was activity dependent,
we raised the ﬂies in the dark. As seen in Fig. 5l,p, this did not
prevent the degeneration, showing that neuronal activity is not
affecting the degeneration. To further assess a connection
between degeneration and photoreceptor activity, we directly
measured activity using electroretinograms (ERGs). Again, we
could not detect any defects neither in young ﬂies (1–3 days old)
nor in aged ones (28–30 days old, Supplementary Fig. 3), which
strongly suggests that phototransduction is not affected by the
loss of SWS.
Mutations in PNPLA6 alters phospholipid levels. Loss of SWS/
PNPLA6 results in increased PC levels in ﬂies and mice10,13. We
therefore predicted that sws1 Drosophila as well as our OMS
patients may show abnormalities in phospholipid levels due to
lower PNPLA6 enzymatic activity. If true, this may then provide a
tool for clinical diagnoses and potentially provide a therapeutic
target. Based on the phospholipid metabolism showed in Fig. 6a,
we predicted that mutant PNPLA6 (NTE) would result in
elevated PC, LPC and LPA levels. This was conﬁrmed using mass
spectrometry analysis of these phospholipids in extracts from
whole wild-type and mutant Drosophila (Fig. 6b). We also
measured phospholipid levels in serum from family 1 (5,267) and
family 3 (166–171) members. We found on average 10–15%
increased levels of PC, LPA and LCA in patients and mutation
carriers compared with controls (data not shown). However, as
levels of these phospholipids are found to vary about two- to
sixfold in normal human plasma/serum samples, with limited
sample size and no opportunity to replicate these measurements
in additional patients, the detected changes did not reach
statistical signiﬁcance.
Discussion
Our results suggest that PNPLA6 is essential for vision and
photoreceptor biology, and that mutations in PNPLA6 cause
photoreceptor neuron death and blindness in children with OMS
Figure 3 | Retinal phenotypes of children with PNPLA6 mutations. (a) A retinal photo shows severe choroidal and retinal atrophy ‘choroideremia
like’ in patient 5,267. (b) Fundus autoﬂuorescence (FAF) shows severely abnormal and grossly absent lipofuscin metabolism. (c) Optical coherence
tomography reveals severe photoreceptor loss, retinal thinning and retinal remodelling. (d) Using optical coherence tomography, we found that the inner
retinal layers are also abnormal. (e) Another child (167) with mutations in PNPLA6 shows a strikingly similar retinal appearance as shown in a, again
illustrating the ‘choroideremia-like’ retinal changes. (f) Full-face photo of a child with PNPLA6 mutations, illustrating the extremely long lashes.
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and LCA. Moreover, this report documents the ﬁrst gene for
OMS and the 20th gene for LCA. Finding PNPLA6 mutations in
various forms of childhood blindness was unexpected, because
mutations and organophosphate-induced changes in PNPLA6 are
observed in two neurological disorders with large motor neuron
disease, spastic paraplegia (SPG39) and organophosphate-
induced neuropathy (OPIDN). SPG39 and OPIDN are severe
diseases but do not present with photoreceptor degeneration.
Why do the mutations in PNPLA6 described here cause
photoreceptor cell death, while patients with SPG39 and OPIDN
do not? One explanation is that the PNPLA6 mutations in ﬁve
out of seven of our families were compound heterozygotes, with
one mutation in the regulatory and one mutation in the catalytic
domain (Fig. 2b and Supplementary Fig. 1). SPG39 patients have
homozygous mutations in the catalytic (patatin) domain12,16. In
OPIDN patients, the organophosphates bind to and inhibit only
the catalytic domain and the N-terminal functions may not be
affected. Having mutations in both domains may cause a more
severe overall impairment of PNPLA6 function, leading to
photoreceptor death. Alternatively, the mutations in the
N-terminal regulatory domain might induce speciﬁc
phenotypes. It is also possible that the harmful effects of
organophosphates are not strong enough to affect retinal
photoreceptors but only large neurons, such as motor neurons.
It will be possible to test this hypothesis in future experiments.
PNPLA6 has been known for over 45 years and despite intense
investigations (600þ publications), its various functions have not
been fully elucidated13. Previously, PNPLA6 was found to be
expressed in the brain, most prominently in large (motor)
neurons, but not in the retinal tissue2,17. We now show (Fig. 4)
that PNPLA6 is expressed in the developing and mature mouse
retina in horizontal, amacrine and photoreceptors cells, and in
Drosophila photoreceptors. Unlike mouse neurons, where
PNPLA6 localizes to the ER12,18, we show here that PNPLA6 is
mostly localized to the IS plasma membrane of mouse
photoreceptors, suggesting a possible role for PNPLA6 in the
formation of distinct plasma membrane domains in the IS and in
the OS, or in the development/renewal of OS disc membranes,
which are essential for maintaining the integrity of the
photoreceptors and vision16,19,20. Previous studies indeed
support a role for PNPLA6 in membrane growth, as
knockdowns of Pnpla6 in zebraﬁsh caused axonal truncation
and abnormal branching in addition to small eyes17.
Furthermore, it was proposed that altered membrane trafﬁcking
in neuronal-speciﬁc Pnpla6 knockout mice causes axonal
degeneration in spinal neurons13.
Similar to vertebrates, SWS is expressed in photoreceptor cells
in ﬂies. Although the photoreceptors develop normally in
mutants, the eye-speciﬁc knockdown of SWS shows severe
photoreceptor degeneration when aged, revealing that SWS is
crucial for photoreceptor maintenance but not development. In
addition, the degeneration is not dependent on light input,
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Figure 4 | PNPLA6 expression in the mouse and Drosophila retina.
(a) Section of a mouse retina superimposed with illustrations of the cell
types found in the three different layers. onl, outer nuclear layer; inl, inner
nuclear layer; gcl, ganglion cell layer; os, outer segment; is, inner segment;
r, rod; c, cone; mu, Mu¨ller cell; rgc, retinal ganglion cell; bi, bipolar cell;
h, horizontal cell; am, amacrine cell. (b) Illustration of a Drosophila retina
along the longitudinal axis. ant, anterior; pos, posterior; re, retina; la, lamina.
(c) Immunostaining for SWS in longitudinal sections of ﬂy retina. SWS is
expressed surrounding the nuclei and along the entire length of the
photoreceptor (arrowheads). bm, basement membrane; c, cornea; re,
retina. (d–f) Time course of PNPLA6 expression in the mouse retina, as
indicated. PNPLA6 is expressed in cells of the inner and outer retina at all
stages examined (arrowheads), as well as in the photoreceptor inner
segment area (asterisk). Co-immunostaining of mouse retinal sections at
P5 with PNPLA6 and the horizontal cell marker neuroﬁlament-165 (NF-165;
g–i), amacrine cell marker syntaxin (j–l) and the photoreceptor cell marker
Naþ/Kþ-ATPase (m–o). Arrowheads point to positive cells and asterisks
point to area of positive staining. (p–r) Confocal z-stack projection of an
adult mouse retinal sections (P30) co-immunostained with PNPLA6 and
the photoreceptor inner segment plasma membrane marker Naþ /Kþ-
ATPase. PNPLA6 localizes mostly to the plasma membrane, although some
staining is detected inside the inner segment. (s–u) Co-immunostaining of
PNPLA6 with the cone photoreceptor marker peanut agglutinin (PNA)
showing expression of PNPLA6 in cones (arrow). Sections were
counterstained with Hoechst (blue) to reveal nuclei.
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showing that the degeneration is not activity dependent. This
suggests that the degeneration is caused by a failure to maintain
the integrity of the photoreceptor cells and not by deleterious
effects due to alterations in photoreception. This is also in
agreement with the fact that the loss of SWS in other neurons also
causes a progressive degeneration.
In agreement with the role of PNPLA6 as a phospholipase, we
found alterations in phospholipid composition (LPC, LPA and
PC) in Drosophila. We carefully examined the wild type, sws
mutants and heterozygotes. Interestingly and importantly, we
show a signiﬁcant accumulation of all, LPA, LPC and LC, which
may explain some of the clinical features of OMS. Indeed,
elevated concentrations of LPA are known to be cytotoxic to
neuronal cells, including photoreceptors21, and defects in the LPC
acyltransferase-1, an enzyme catalysing the conversion of LPC to
PC, cause photoreceptor degeneration in mice22. LPA also
promotes hair growth23 and defects either in LPA
production24,25 or LPA signalling26,27 are associated with hair
growth abnormalities, as observed in our OMS patients. It is
therefore possible that elevations in LPA lead to the trichomegaly,
wooly hair and progressive alopecia in our OMS patients. Altered
LPA signalling may also be responsible for the abnormalities in
bone and tooth development28, and growth hormone
deﬁciency25, also seen in our OMS patients (Table 1).
Interestingly, transient juvenile trichomegaly and progressive
alopecia, as well as a strong family history of different early-onset
cancers29 were also found in some of our families (data not
shown). However, this link needs to be further explored.
Most of the identiﬁed mutations in OMS are in highly
conserved residues, supporting their functional importance and
potential use for rapid clinical testing of OMS and LCA patients.
Our studies have opened a new avenue in investigating functions
of PNPLA6, including whether single PNPLA6 mutations increase
photoreceptor susceptibility to environmental toxins. In the near
future, it will be interesting to generate and characterize a
photoreceptor-speciﬁc Pnpla6 mouse knockout to study the
fundamental mechanism of action of PNPLA6 and evaluate the
potential therapeutic beneﬁts of lowering LPC and LPA.
Methods
Patient information. Patients were phenotyped at several international centres,
after informed consents were obtained, approved by the ethical and scientiﬁc
review boards. Detailed ophthalmological evaluations were followed by medical
and clinical genetics consultations. All patients underwent a detailed history and
pedigree analysis and detailed eye examinations, including best-corrected visual
acuities by projected Snellen charts, near vision, slitlamp biomicroscopy and dilated
retinal exams. In vivo retinal imaging was performed by the Heidelberg OCT
(Heidelberg Engineering), followed by fundus autoﬂuorescence. Kinetic ﬁelds
were measured by Goldmann perimetry. In selected patients, we performed
International Society for Clinical Electrophysiology of Vision (ISCEV) standard
ERGs and multifocal ERGs (Diagnosys, Boston, USA). Peripheral blood was col-
lected in lavender top (EDTA) tubes for DNA extraction.
R1
LA
RE
R2R3
R4
R5 R6
R7
Figure 5 | Loss of SWS causes photoreceptor degeneration in Drosophila. Electron microscopy studies from a 3-week-old wild-type ﬂy show intact
ommatidia with seven photoreceptor cells (R1–7) present (a,e; arrowheads in a point to the photoreceptor cell somata). Performing sections from the retina
of a sws1 mutant ﬂy shortly before eclosion (pharate adult) shows that photoreceptors develop normally (b) and persist during the ﬁrst 2 weeks of
adulthood (c, 14 days), although occasionally ommatidia missing a single photoreceptor can be found (arrow). However, after 23 days of ageing (which, due
to the reduced live span of sws1, is shortly before these ﬂies die), photoreceptor degeneration is evident in all ommatidia by the loss of photoreceptors
(arrows in d), and in the condensed and darkly stained cell somata of the photoreceptors that are still present (arrowheads). In addition, vacuoles can be
found in the somata (arrowheads in f,h) and the rhabdomeres are shrunken. In some photoreceptors, membranous structures can be found (arrow in g).
Knocking down SWS speciﬁcally in the eye using an RNA interference (RNAi) construct expressed by GMR-GAL4 showed that newly enclosed ﬂies look
normal with all the seven photoreceptors R1–7 present (i,m). At 7 days of age the ommatidia still look wild type (j,n), but at 4 weeks the photoreceptors
clearly show degeneration with vacuoles forming in the photoreceptor somata (arrows in k,o) and loss of some photoreceptors (arrowhead in k). Raising
the ﬂies in the dark resulted in a comparable photoreceptor degeneration in 30-day-old ﬂies (l,p). Scale bar, 4mm (a), 2 mm (e).
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Animals. All animal work was carried out in accordance with the Canadian
Council on Animal Care guidelines and was approved by the Institut de recherches
cliniques de Montre´al Animal Care Committee. CD1 and C57/Bl6 mice of either
sex were used in this study.
WES analysis. DNA was extracted from whole blood using the FlexiGene kit or
the QIAamp DNA blood kit according to the manufacturer’s protocol. DNA
quantity and quality were veriﬁed by using NanoDrop. The exomes of two sporadic
cases (5,273 and 5,267) and all individuals from the Czech family 3 (166–171) with
childhood blindness and OMS were captured by the Sure Select Human Exome Kit
version 4 (Agilent Technologies, Inc., Santa Clara, CA), using 3 mg of genomic
DNA of each. Exon-enriched DNA libraries were then sequenced either on Illu-
mine HiSeq2000 that generate 100 bp paired-end reads or on SOLiD 4 that gen-
erate 50 bp reads. The details of bioinformatics analysis have been reported
previously30–33. Brieﬂy, the high-quality trimmed reads from Illumina HiSeq2000
were aligned to the positive strand of human genome (hg19) by BWA version 0.5.9
(ref. 29) and a mean coverage of 128 (5,273) and 131 (5,267) was obtained for
the targeted coding regions (consensus coding sequence). Reads from SOLiD 4
were aligned using Novoalign version 2.08.03. Quality score recalibration was
performed during alignment and reads that aligned to multiple locations were
discarded. Following alignment PCR, duplicate reads were removed using Picard
tools version 1.84. Variant calling and annotation were performed by SAMtools
version 0.1.7 (ref. 34) and ANNOVAR35, respectively. Filtering steps were carried
out with public (dbsnp135, 1,000 genome project and NHLBI exomes) and our
in-house exome (contains more than 800 samples) databases. Subsequently,
variants that were predicted to be protein-altering (that is, missense, nonsense,
frameshift, or canonical splice site changes) were prioritized and were manually
examined in IGV36. Variants identiﬁed in individuals from Czech family 3 were
also used for homozygosity mapping, linkage analysis and detection of copy-
number variants.
Sanger sequencing and co-segregation. The selected variants were conﬁrmed by
Sanger sequencing in the patients and co-segregation was tested in their family
members on an ABI 3730xl capillary sequencers. The Sanger sequencing results
were analysed with the Sequencher software. Mutations were excluded from nor-
mal controls (at least 100 normal controls) and co-segregation in the family was
studied. All mutations were studied by in silico analysis (Pmut, Blossum62, SIFT
and Polyphen). All patients had two mutations, either homozygous or compound
heterozygous. To ensure the completeness and quality of the sequences, primers
were designed from intron sequences so that the entire exon and at least 50 bp of
intron DNA on each side of each exon were ampliﬁed. Primers for the PCRs were
designed by primer3 (http://frodo.wi.mit.edu/primer3/).
Drosophila PNPLA6 localization and knockout experiments. The 50-mm
vibratome head sections from white-eyed ﬂies (w1118, to avoid interference by the
autoﬂuorescence from the eye pigment) were performed as described in Bolkan
et al.37 and stained with our anti-SWS serum at a dilution of 1:100. Detection was
done with a biotinylated secondary antibody (1:200; Vector Laboratories) and a
Cy5-conjugated streptavidin (1:100; Jackson ImmunoResearch). Sections were
counterstained with DAPI (40,6-diamidino-2-phenylindole; Invitrogen). Optical
images (0.5 mm thick) were taken on an Olympus FW1000 confocal microscope.
Semi-thin and ultra-thin Epon plastic sections were prepared as described in ref.
15. Semi-thin sections (1mm) were stained with 1% toluidine blue and 1% borax,
and analysed by light microscopy. Ultra-thin sections were analysed with a FEI
Morgagni 268 electron microscope. sws1 is described in Kretzschmar et al.15 DTM-
SWS was created by deleting aa1–55, which includes the N terminus and the ﬁrst
transmembrane domain. The eye-speciﬁc knockdown was achieved by inducing
the JF03428 RNA interference construct with GMR-GAL4 (both from the
Bloomington Stock Center). Flies were raised and aged under standard conditions
at 25 C.
Mouse PNPLA6 immunostaining. Eyes were enucleated and ﬁxed by immersion
in freshly prepared 4% paraformaldehyde in PBS for 3 h on ice. For adult eyes, a
small incision was made along the ora serrata after 10min in paraformaldehyde, to
allow better access to the ﬁxative. The eyes were then rinsed in PBS and cryo-
protected in sucrose 20% overnight, frozen and embedded in a sucrose:optimal
cutting temperature (O.C.T.) compound (1:1) mix. For immunoﬂuorescence,
retinas were sectioned and processed for staining on the same day. Slides were
preincubated for 1 h in blocking buffer (20% goat serum in 0.2% Triton) and then
incubated 48 h at 4 C with primary antibodies diluted in PBS. Primary antibodies
used were PNPLA6 (NTE; 1/100, Abcam), Na2þKþ -ATPase (1/100, Thermo
Scientiﬁc), Syntaxin (1/500, Sigma), NF-165 (1/200, gift from B. Barres, Stanford
U.) and Brn3b (1/100, Santa-Cruz). Bound antibodies were detected using
appropriate secondary antibodies conjugated with Alexa 488, 555, 594 or 647
(1:1,000; Invitrogen) diluted in antibody buffer at room temperature for 1 h. In all
cases, nuclei were counterstained with Hoechst 33342 (Molecular Probes).
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Figure 6 | Phospholipid metabolism is altered in SWS mutant ﬂies. (a) PNPLA6 (NTE)-related metabolic pathway. POC, phosphorylcholine; GPC,
glycerolphosphocholine; LPC, lysophosphatidylcholine; LPA, lysophosphatidic acid; LPARs, lysophosphatidic acid receptors; PCH, phosphatidylcholine;
PA, phosphatidic acid; GPCDE, glycerolphosphocholinediesterase; NTE, neuropathy target esterase; LCAT, lecithin-cholesterol acyltransferase; PLA1,
phospholipase A1; PLA2, phospholipase A1; PLB, phospholipase B; LPCH, lysophosphatidylcholine hydrolase; LIPH, lipase H; ATX, autotaxin. (b) Elevated
PC, LPC and LPA levels in SWS mutant ﬂies. Wild-type Drosophila (CS), (n¼ 8); mutant heterozygotes (SWS/CS), n¼4; sws1-null mutants (SWS), n¼ 5.
PC, LPC and LPA levels (y axis) are expressed in pmol of individual compounds per mg of protein. The means±s.d. for individual groups and P-values
(t-test) are indicated; *Pr0.05, **Pr0.01, ***Pr0.001; n.s., not signiﬁcant. Experiments were repeated twice.
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Extraction of Drosophila phospoholipids for ﬂow injection-electrospray ioni-
zation-tandem mass spectrometry analysis. Whole ﬂies were homogenized in
MilliQ water to acquired concentration 80mgml 1. Homogenization was per-
formed with Branson Digital Soniﬁer 450 working as cup horn set to pulse mode (1 s
pulse/1 s pause) with amplitude maximum at 100watt each sample was total
homogenization time was 2 30 s. The 250ml of ﬂy homogenates was extracted by
modiﬁed method of Natomi38. Fly homogenates (250ml) corresponding to 20mg was
extracted by 2ml of mixture of chloroform:methanol:water (20:10:1 v/v/v). Extraction
mixture was repeatedly vortexed in 15-min steps during 2 h and then left at  20 C
overnight. Supernatant was ﬁltered through glass ﬁlter to a glass tube. Sediment was
re-extracted with 2ml of mixture of chloroform:methanol:water (10:10:1 v/v/v).
Extraction mixture was vortexed for 1 h and then ﬁltered through glass ﬁlter and
combined with the ﬁrst extract. Final re-extraction step was with 2ml mixture of
chloroform:methanol:water (10:20:1 v/v/v). The mixture was vortexed for 1 h and
then ﬁltered through glass ﬁlter and combined with previous extracts. The combined
supernatants were dried under a stream of nitrogen. Aliquot corresponding to 1mg
of ﬂies was mixed with 50 pmol of internal standards: C17:0 LPC, C17:0 LPA and
C10:0PC (Avanti Polar Lipids Inc., Alabaster, Alabama, USA) and reconstituted in
1ml of methanol with 5mM NH4COOH (to generate [MþH]þ ions) or in pure
methanol in the case of LPA (to generate [M-H]- ions). Samples were introduced by
ﬂow injection with tandem mass spectrometry (MS/MS).
Phospholipids analysis by FIA-ESI-MS/MS. Mass spectra were obtained on an
ABI/MDS SCIEX API 4000 tandem mass spectrometer equipped with an
electrospray ionization (ESI) source and coupled to an Agilent HPLC 1290 series.
PC and LPC were analysed by multiple reaction monitoring scans using
common product ion with 184.1 m/z (phosphocholine) in the positive ion mode.
Transition pairs were monitored for 100ms and their m/z were as follows: LPC—
494.3-184.1 (C16:1); 496.5-184.1 (C16:0); 520.4-184.1 (C18:2); 522.5-184.1
(C18:1); 524.5-184.1 (C18:0); 510.4-184.1 (C17:0 IST); PC: 732.6-184.1
(C32:3); 734.6-184.1 (C32:2); 742.6-184.1 (C33:3); 744.6-184.1 (C33:2);
746.6-184.1 (C33:1); 758.6-184.1 (C34:2); 760.6-184.1 (C34:1); 762.6-184.1
(C34:0); 780.6-184.1 (C36:3); 782.6-184.1 (C36:2); 784.6-184.1 (C36:1);
786.6-184.1 (C36:0); 794.7-184.1(C37:3); 796.7-184.1 (C37:2); 806.6-184.1
(C38:4); 808.6-184.1 (C38:3); 810.6-184.1 (C38:2); 812.7-184.1 (C38:1);
814.7-184.1 (C38:0); 426.6-184.1 (C10:0 IST). The ESI condition were as
follows: curtain gas (N2), 14 psi; collision gas (N2), 7 psi; source gas 1 (N2), 20 psi;
source gas 2 (N2), 50 psi; nebulizing gas (N2) temperature, 200 C; the capillary
spray voltage was 5.5 kV, interface heater, ON. The ion optics settings for PC and
LPC measurements were: 98V for the declustering potential and 3V for the
entrance potential. The collision energy was set to 35V, with a collision cell exit
potential of 11V. LPA was analysed by negative multiple reaction monitoring using
152.8 m/z product ion for LPA (glycerolphosphate): LPA 409.2-152.8 (C16:);
433.3-152.8 (C18:2); 435.4-152.8 (C18:1); 437.3-152.8 (C18:0); 457.2-152.8
(C20:4); 423.3-152.8 (C17:0 IST), and scan times for each transition pair was
500ms. The ESI condition were as follows: curtain gas (N2), 14 psi; collision gas
(N2), 12 psi; source gas 1 (N2), 5 psi; source gas 2 (N2), 25 psi; nebulizing gas (N2)
temperature, 200 C; the capillary spray voltage was  4.5 kV, interface heater, ON.
The ion optics settings for LPA measurement were:  118V for the declustering
potential and  10.7V for the entrance potential. The collision energy was set to
 35V with a collision cell exit potential of  5V.
PC, LPC and LPA concentrations were calculated using known amount
(50 pmol) of internal standard added to samples. Final concentrations were
expressed as pmol of lipids per mg of Drosophila. The Analyst 1.5 software was
used to operate the instruments and process the data.
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